No connection

Search Results

LEGN vs LQDA

LEGN
Legend Biotech Corporation
BEARISH
Price
$18.16
Market Cap
$3.36B
Sector
Healthcare
AI Confidence
85%
LQDA
Liquidia Corporation
NEUTRAL
Price
$38.85
Market Cap
$3.42B
Sector
Healthcare
AI Confidence
75%

Valuation

P/E Ratio
LEGN
--
LQDA
--
Forward P/E
LEGN
15.79
LQDA
7.42
P/B Ratio
LEGN
3.35
LQDA
75.73
P/S Ratio
LEGN
3.26
LQDA
21.62
EV/EBITDA
LEGN
-48.64
LQDA
-68.03

Profitability

Gross Margin
LEGN
20.03%
LQDA
91.64%
Operating Margin
LEGN
-6.72%
LQDA
21.5%
Profit Margin
LEGN
-28.85%
LQDA
-43.54%
ROE
LEGN
-29.06%
LQDA
-111.05%
ROA
LEGN
-5.01%
LQDA
-11.5%

Growth

Revenue Growth
LEGN
64.2%
LQDA
3054.6%
Earnings Growth
LEGN
--
LQDA
--

Financial Health

Debt/Equity
LEGN
0.41
LQDA
4.42
Current Ratio
LEGN
1.96
LQDA
2.01
Quick Ratio
LEGN
1.88
LQDA
1.8

Dividends

Dividend Yield
LEGN
--
LQDA
--
Payout Ratio
LEGN
0.0%
LQDA
0.0%

AI Verdict

LEGN BEARISH

LEGN exhibits severe financial instability as evidenced by a critical Piotroski F-Score of 1/9, indicating poor operational health. While the company shows impressive top-line revenue growth of 64.20%, this is offset by consistent earnings misses (average surprise of -66.26% over the last 4 quarters) and a devastating technical trend (0/100). There is a stark disconnect between the bullish analyst target of $57.22 and the actual price performance, which has declined over 41% in the last year. The stock currently behaves as a high-risk speculative asset with failing fundamental health markers.

Strengths
Strong YoY revenue growth of 64.20%
Low Debt/Equity ratio of 0.41
Healthy liquidity with a Current Ratio of 1.96
Risks
Critical Piotroski F-Score (1/9) indicating fundamental weakness
Severe technical breakdown with 0/100 trend score
Consistent failure to meet earnings estimates (1/4 beats in last 4 quarters)
LQDA NEUTRAL

Liquidia Corporation presents a high-risk, high-reward profile characterized by a critical Piotroski F-Score of 1/9, indicating severe fundamental weakness. While the company has achieved explosive revenue growth (3054.60% YoY) and maintains a strong gross margin of 91.64%, its balance sheet is distressed with a Debt/Equity ratio of 4.42 and an ROE of -111.05%. The market is pricing in significant future success, as evidenced by a Price/Book ratio of 75.73, though insider selling and a bearish technical trend suggest a potential near-term peak. The disconnect between analyst optimism (Buy rating) and deterministic health scores necessitates a neutral stance.

Strengths
Explosive revenue growth of 3054.60% YoY
Exceptional gross margins (91.64%) typical of high-value specialty drugs
Positive operating margin (21.50%) suggesting core business viability
Risks
Critical fundamental health (Piotroski F-Score 1/9)
Extreme valuation premiums (Price/Book 75.73, Price/Sales 21.62)
High leverage with a Debt/Equity ratio of 4.42

Compare Another Pair

LEGN vs LQDA: Head-to-Head Comparison

This page compares Legend Biotech Corporation (LEGN) and Liquidia Corporation (LQDA) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile